The Need for a Practical Dosimetry Paradigm That Incorporates Dose Heterogeneity

Lam, Marnix G.E.H.; Kappadath, S. Cheenu

doi:10.1016/j.jvir.2024.02.024

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The availability of flexible dose shipping options may have resulted in different dose/sphere values for different administrations, resulting in varying sphere density and dose uniformity/heterogeneity. 24 , 25 This important point might cause misinterpretation of the actual dose-response relationship. Finally, the current study included chemorefractory CRCLM patients with extensive prior treatment, therefore the results may not reflect the TARE for patients with less prior treatment.…”

Section: Discussionmentioning

confidence: 99%

Are survival outcomes dependent on the tumour dose threshold of 139 Gy in patients with chemorefractory metastatic colorectal cancer treated with yttrium-90 radioembolization using glass particles? A real-world single-centre study

Topcuoglu,

Orhan,

Gormez

et al. 2024

British Journal of Radiology

View full text Add to dashboard Cite

Objectives To compare the survival and objective response rate (ORR) of the patients receiving estimated tumor absorbed dose (ETAD) <140 Gy versus ETAD ≥140 Gy in patients with advanced chemorefractory colorectal carcinoma liver metastases (CRCLM) treated with yttrium-90 transarterial radioembolization (90Y TARE). Materials and Methods Between August 2016 and August 2023 adult patients with unresectable, chemorefractory CRCLM treated with 90Y TARE using glass particles, were retrospectively enrolled. Primary outcomes were overall survival (OS) and hepatic progression free survival (hPFS). Secondary outcome was ORR. Results A total of 40 patients with a mean age of 66.2 ± 7.8 years met the inclusion criteria. Mean ETAD for the group 1 (ETAD <140 Gy) and group 2 (ETAD ≥140) were 131.2 ± 17.4 Gy versus 195 ± 45.6 Gy, respectively. The mean OS and hPFS for group 1 versus group 2 were 12 ± 10.3 months and 8.1 ± 9.3 months versus 9.3 ± 3 months and 7.1 ± 8.4 months, respectively and there were no significant differences (p = 0.181 and p = 0.366, respectively). ORR did not show significant difference between groups (p = 0.432). Conclusion In real-world practice, no significant difference was found in OS, hPFS and ORR between patients who received ETAD <140 Gy versus ETAD ≥140 Gy in patients with CRCLM, in this series. Advances in knowledge This study demonstrated that increased tumour absorbed doses in radioembolization may not provide additional significant advantage for OS and hPFS for patients with CRCLM.

show abstract

Section: Discussionmentioning

confidence: 99%